Please login to the form below

Not currently logged in
Email:
Password:

Dan Zabrowski takes over as head of Roche Applied Science

Former global head of partnering succeeds Paul Brown

Dan Zabrowski - RocheRoche's Dan Zabrowski has assumed his new role as head of Roche Applied Science within the company's diagnostics division.

Zabrowski was previously global head of partnering at Roche and also sat on both the Roche corporate executive committee and the board of Roche's Japan-based subsidiary Chugai.

He will succeed Paul Brown, who has been in charge at Roche Applied Science since September 2011, and will relocate from Basel, Switzerland, to Penzberg, Germany. Once there Brown will remain head of Roche Molecular Diagnostics.

Zabrowski joined Syntex in 1993, before Roche acquired the company in 1994.

He has been with Roche ever since, holding a number of management positions in regulatory affairs and pharma development. He also holds a PhD in organic chemistry from the University of Indiana.

Roche CEO Severin Schwan said: “As head of applied science, Dan will be key for driving this strategically important business with our customers in academia, biotech and pharmaceutical industries.”

As previously announced, general manager of Roche Pharma in France Sophie Kornowski-Bonnet will take over Zabrowski's old role as head of partnering and relocate to the company's Basel-based headquarters.

2nd February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics